Seguridad del empleo de regadenosón como fármaco vasodilatador en resonancia magnética cardíaca de estrés

Montalescot, 2013, 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology, Eur Heart J., 34, 2949, 10.1093/eurheartj/eht296 Windecker, 2014, Eur Heart J., 35, 2541, 10.1093/eurheartj/ehu278 Danad, 2017, Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis, Eur Heart J., 38, 991 Bruder, 2013, European Cardiovascular Magnetic Resonance (EuroCMR) registry--multi national results from 57 centers in 15 countries, J Cardiovasc Magn Reson., 15, 9, 10.1186/1532-429X-15-9 Zoghbi, 2012, Selective adenosine agonists and myocardial perfusion imaging, J Nucl Cardiol., 19, 126, 10.1007/s12350-011-9474-9 Beretta, 2009, Pruebas de estrés farmacológico en cardiología nuclear, Rev Urug Cardiol., 24, 112 Al Jaroudi, 2009, Regadenoson: A New Myocardial Stress Agent, J Am Coll Cardiol., 54, 1123, 10.1016/j.jacc.2009.04.089 Prenner, 2012, A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease, J Nucl Cardiol., 19, 681, 10.1007/s12350-012-9547-4 Nguyen, 2014, Safety and tolerability of regadenoson CMR, Eur Heart J Cardiovasc Imaging., 15, 753, 10.1093/ehjci/jet278 Hundley, 2009, Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations, J Cardiovasc Magn Reson., 11, 5, 10.1186/1532-429X-11-5 Kawel-Boehm, 2015, Normal values for cardiovascular magnetic resonance in adults and children, J Cardiovasc Magn Reson., 17, 29, 10.1186/s12968-015-0111-7 Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr., 28, 1, 10.1016/j.echo.2014.10.003 Cerqueira, 2002, Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association, Circulation., 105, 539, 10.1161/hc0402.102975 Hendel, 2005, Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging, J Am Coll Cardiol., 46, 2069, 10.1016/j.jacc.2005.05.097 2013 American Society of Nuclear Cardiology /MedAxiom Nuclear Survey. J Nucl Cardiol. 2014;21 Suppl 1:5-88. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001176/WC500097100.pdf. Vasu, 2013, Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance, J Cardiovasc Magn Reson., 15, 85, 10.1186/1532-429X-15-85 Cerqueira, 1994, Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry, J Am Coll Cardiol., 23, 384, 10.1016/0735-1097(94)90424-3 Ranhosky, 1990, The safety of intravenous dipyridamole thallium myocardial perfusion imaging, Intravenous Dipyridamole Thallium Imaging S*tudy G*roup. Circulation., 81, 1205 Kidambi, 2016, Factors associated with false-negative cardiovascular magnetic resonance perfusion studies: A Clinical evaluation of magnetic resonance imaging in coronary artery disease (CE-MARC) substudy, J Magn Reson Imaging., 43, 566, 10.1002/jmri.25032 Mishra, 2005, Quantitative relation between hemodynamic changes during intravenous adenosine infusion and the magnitude of coronary hyperemia: implications for myocardial perfusion imaging, J Am Coll Cardiol., 45, 553, 10.1016/j.jacc.2004.10.064 Hage, 2011, The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease, Am Heart J., 162, 356, 10.1016/j.ahj.2011.05.014 Hage, 2010, Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome, Am J Cardiol., 105, 839, 10.1016/j.amjcard.2009.11.042 Hage, 2009, Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus, Am Heart J., 157, 771, 10.1016/j.ahj.2009.01.011 Hage, 2011, A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging, J Nucl Cardiol., 18, 1086, 10.1007/s12350-011-9429-1 DiBella, 2012, The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study, Int J Cardiovasc Imaging., 28, 1435, 10.1007/s10554-011-9949-4 Motwani, 2018, Role of cardiovascular magnetic resonance in the management of patients with stable coronary artery disease, Heart., 104, 888, 10.1136/heartjnl-2017-311658 Denevich, 2010, PCV88 Economic evaluation of the use of regadenoson in myocardial perfusion imaging: cardiovascular laboratory perspectives, Value Heal., 13, A166, 10.1016/S1098-3015(10)72807-2